U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease

CRANBURY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news